Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Pharmacotherapy for Severe Mood Dysregulation
NCT01714310Phase 2Completed
- Sponsor
- University of California, Los Angeles
- Start
- Jan 2013
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisdexamfetamine in disruptive mood dysregulation disorder (DMDD), sponsored by University of California, Los Angeles. Started Jan 2013; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
disruptive mood dysregulation disorder (DMDD)
Beyond the preview
Go deeper on NCT01714310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01714310.